Hondros College Nur 160 Medications Q&A Latest Update 2025-2026
Course:
NUR 160
Institution:
NUR 160
Hondros College Nur 160 Medications Q&A Latest Update 2025-2026
After purchase, you get:
✅ Instant PDF Download
✅ Verified answer explanations
✅ Refund if not Satisfied
✅ Prepared for 2025/2026 test cycle
Document Information
| Uploaded on: | April 30, 2025 |
| Last updated: | May 12, 2025 |
| Number of pages: | 6 |
| Written in: | 2025/2026 |
| Type: | Exam (elaborations) |
| Contains: | Questions & Answers |
| Tags: | Hondros College Nur 160 Medications Q&A Latest Update 2025-2026 |
Seller Information
AdelineJean
User Reviews (0)
Exam (Elaborations)
$7.00
Bundle Deal! Get all 8 docs for just $22.50
Add to Cart
100% satisfaction guarantee
Refund Upon dissatisfaction
Immediately available after purchase
Available in Both online and PDF
$7.00
| 0 sold
Discover More resources
Available in a Bundle
Package Deal for Hondros NURS 160 Exams Questions and Verified Answers 2025-2026 Update
Includes 8 Documents
$22.50
Content Preview
Hondros College Nur 160 Medications | Q&A Latest 2025/2026 | 100% PASS morphine - Answer -(MS Contin, Morphine Sulfate, Avinza) Opioid, narcotic Uses: pain related to surgery, trauma, cancer, visceral and moderatesevere pain Other uses: suppresses cough and slows GI motility MOA: bind to opiod receptore mimicking effects of analgesic peptides Side effects: decreased mental alertness, euphoria, dysphoria, RESPIRATORY DEPRESSION, constipation, nausea, vomiting, bronchoconstriction, decreased urination, bradycardia -closely monitored by FDA, schedule II drug acetaminophen/oxycodone - Answer -(Percocet) Class: opioid and acetaminophen, schedule II Uses: moderate-severe pain Nursing considerations: helps the dose of the narcotic to be kept small to avoid dependence and side effects. Use in caution with additional acetaminophen in regards to recommended daily dose of 4gm Side effects: same as opioids
Gradesity
We are here to help
Questions? Leave a message!
Newsletter
Get notified upon new uploads. Subscribe to our Newsletter.
